Featured Press Releases

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

BioMarin to Present Data Showcasing VOXZOGO® (vosoritide)

BioMarin to Present Data Showcasing VOXZOGO® (vosoritide)'s Impact on Bone Health and Quality of Life in Achondroplasia

  • 17 Jun 2024

BioMarin Pharmaceutical Inc. announced the presentation of new data from an investigator-led...

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Presents Late-Breaking Data on BOLD-100’s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

MTF Biologics and Kolosis BIO introduce Summit Matrix™, expanding solutions for orthopedic and spinal surgeries

MTF Biologics and Kolosis BIO introduce Summit Matrix™, expanding solutions for orthopedic and spinal surgeries

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

CollPlant Expands Its rhCollagen 3D Bioprinting Portfolio Through the Launch of Ready-to-Print BioFlex

  • CollPlant
  • 24 Feb 2026
With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

With timsOmni™ Mass Spectrometry, Bruker Advances Functional Proteomics 2.0 for Deeper Insights into Disease Biology

  • Bruker Corporation
  • 24 Feb 2026
SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

  • Clarity Pharmaceuticals
  • 23 Feb 2026
PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

PureTech Secures U.S. and EU Orphan Designations for Deupirfenidone (LYT-100) in IPF

  • PureTech Health plc
  • 20 Feb 2026
ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

ENFLONSIA™ (clesrovimab) shows positive new results in infants and children under 2 at increased risk of severe RSV disease across two seasons, Merck reports

  • Merck & Co., Inc.
  • 19 Feb 2026
Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

Gantry-less upright proton therapy for lung cancer re-irradiation shows first-ever prospective clinical results, announced by P-Cure

  • P-Cure
  • 17 Feb 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.